Document:

Exhibit 10.12

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

 

 

Master Service Agreement

 

This Master Service Agreement (“Agreement”),
entered into on May 25th, 2018 by and between CRO Consulting (Pty) Limited, whose Registered Office is at OnQ House 250 Market
Street Fairland Johannesburg 2170 South Africa (hereinafter referred to as "CRO") and Purinix Pharmaceuticals LLC whose
Registered Office is at 1266 East Main Street, Suite 700R, Stamford, CT 06902, USA (hereinafter referred to as “Client”).

 

		1.0	Services

 

		1.1.	Client requires CRO to carry out Clinical Research Services in South Africa (“Services”).
CRO will carry out the tasks agreed and summarised in the Addenda to this Master Service Agreement.

 

		1.2.	This Agreement forms the basis for a working relationship between Client and CRO. This Agreement
will be supplemented, in the form of Project-specific Addenda, as the need arises. The Project-specific Addenda will contain the
detailed requirements of each Project for which Services are contracted to CRO by Client and all fees to be paid by Client.

 

		1.3.	Client will provide CRO with the documents and information necessary as requested by CRO for the
conduct of the Services.

 

		1.4.	CRO agrees to perform the specific tasks set forth in the Project-specific Addenda in a professional
manner, in strict accordance with the terms and conditions contained herein, relevant professional standards including in accordance
with the Protocol and applicable amendments and ICH GCP Guidelines (ICH Harmonised Tripartite Guideline for Good Clinical Practice,
May 1996) and all other relevant laws, rules, regulations and guidelines.

 

		1.5.	CRO agrees to perform these Services according to CRO’s Standard Operating Procedures (SOPs)
or other guidelines as provided, which are provided to Client on request.

 

		1.6	CRO may not subcontract any parts of the Services to a third party without the prior written approval
of Client, which approval shall not unreasonably be withheld. CRO will remain fully liable for the acts and omissions of its employees
and approved subcontractors as if performed by CRO.

 

		1.7	CRO will provide Client with a weekly written report summarizing the Services including all clinical
study activity and any other information reasonably requested by Client.

 

		2.0	Payment

 

		2.1	Client will pay CRO for satisfactory performance of Services as agreed in each Project-specific
Addendum to this Agreement.

 

	 

        Confidential
	 

        Page 1 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive harm if publicly
disclosed.

 

		2.2	Routine telephone calls, mobile calls, faxes and photocopying will be included in the rate provided
by CRO. For clarity, there shall be no payment obligations other than as agreed in each Project-specific Addendum.

 

		2.4	CRO will provide a detailed account of all time and tasks, as against project specific task and
time addenda, and will be payable within 30 days of receipt of invoice by Client.

 

		2.5.	Changes in scope may be incorporated into this Agreement or the Project-specific Addenda upon the
written consent of both parties.

 

		2.6.	In the event of a conflict between the terms of this Agreement and the Project-specific Addenda
the terms of this Agreement shall prevail unless specifically stated in the Project-specific Addenda.

 

		3.0	Period of the Agreement

 

		3.1.	This Agreement shall take effect on the date of signature of the Agreement by both parties and
shall terminate when all obligations required of both parties hereunder are performed unless either terminated earlier or extended
by the parties pursuant to the terms of this Agreement subject to clause 4.0.

 

		4.0	Termination

 

		4.1.	Either party may terminate this Agreement on thirty (30) days written notice if the other materially
breaches this Agreement; provided, however that the party in breach shall have the right to cure such breach within thirty (30)
days after receipt of written notice of the other party’s intention to terminate.

 

		4.2.	Client may terminate this Agreement on thirty (30) days written notice without cause. In the event
of termination by Client for reasons other than default by CRO, Client shall pay all sums owing to CRO, but unpaid, for work performed
to date of receipt of termination notice, and all reasonable and necessary costs associated with the termination itself or to which
CRO is committed to pay. In the event of termination by Client, CRO shall use all efforts to minimize any such costs, including
cancelling orders and services to the extent possible.

 

		4.3.	In the event of early termination under 4.1. above where CRO is in material breach, any credit
held in favour of CRO shall be returned to Client within thirty (30) days following such termination, provided that the Client
will then be liable for all outstanding third party costs lawfully incurred hereunder by CRO prior to the termination.

 

		4.4.	Either party shall be entitled forthwith to terminate this Agreement with immediate effect by written
notice to the other if that other is adjudged insolvent or goes into liquidation (other than for bona fide reconstruction)
or has a receiver appointed over any of its property or assets.

 

		5.0	Warranties, Limitations of Liability and Indemnification

 

		5.1.	CRO warrants to Client that the Services will be performed in a professional and workmanlike manner
and on a best endeavours basis in accordance with the standard of care ordinarily and reasonably expected in the performance of
such Services and that the work performed for Client will be correct in all material respects to the best of the knowledge and
belief of CRO. However, Client acknowledges that the provision of the Services is dependent upon the responsiveness of the South
African regulatory authorities and CRO shall not be held responsible for any acts or omissions of such authorities.

 

	 

        Confidential
	 

        Page 2 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

		5.2.	CRO reserves the right to place staff on the project, however not without initially providing a
project management and resource outline to Client, including but not limited to, the current Curriculum Vitae of proposed staff.
CRO will notify Client of any change in staff. Any new or replacement personnel shall be subject to Client’s prior written
approval, which approval shall not be unreasonably withheld.

 

		5.3.	CRO will utilize CRO business cards, letterheads and facsimile templates for the purpose of the
conduct of this trial.

 

		5.4.	Notwithstanding any other provision of this Agreement, each party’s total liability in respect
of damages under this Agreement, any regulation or common law shall be limited to the sum of all amounts received from Client in
terms of this Agreement; provided, however, that this limitation shall not apply with respect to any claims arising out of or relating
to clause 6 (Inventions and Proprietary Information), indemnification obligations or damages arising from a party’s gross
negligence or willful misconduct.

 

		5.5.	Neither Party shall be liable to the other Party in respect of any indirect loses or damaged, pure
economic nature, loss of profits or income howsoever arising.

 

		5.6.	CRO will defend, indemnify and hold harmless Client and its directors, officers, employees and
agents from and against all liabilities, costs and expenses (including reasonable attorneys’ fees and court costs) arising
from any third party claim, action or lawsuit or other proceeding which is attributable to any negligent or willful act or omission
or breach of this Agreement on the part of CRO or any of its agents or employees in the course of performing CRO’s obligations
hereunder.

 

		5.7.	Client will defend, indemnify and hold harmless CRO and its directors, officers, employees and
agents from and against all liabilities, costs and expenses (including reasonable attorneys’ fees and court costs) arising
from any third party claim, action or lawsuit or other proceeding which is attributable to any negligent or willful act or omission
or breach of this Agreement on the part of Client or any of its agents or employees in the course of performing Client’s
obligations hereunder, including but not limited to breaches of third party intellectual property rights.

 

		6.0	Inventions and Proprietary Information

 

		6.1	CRO agrees that during the term of this Agreement and for a period of three years thereafter:

 

(a)  to disclose and assign
to Client as its exclusive property all inventions and technical or business innovations specifically derived from the work assigned
by Client to CRO which CRO develops or conceives, solely or in conjunction with others (1) that are based on or involve information
of Client, (2) that relate to, constitute, result from, or include the work in which CRO will be engaged for Client, or (3) that
are otherwise made through the use of any time, facilities or materials of Client;

 

	 

        Confidential
	 

        Page 3 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

(b)  that all deliverables
and work products in the form of works of authorship developed by CRO in the performance of Services under this Agreement shall
be deemed works made for hire, and shall belong fully and exclusively to Client; and that if by operation of law such deliverables
or work products are not works made for hire, CRO agrees to, and does hereby, assign to Client all right, title, and interest in
such deliverables or work product, including all copyrights therein;

 

(c)  to execute all necessary
documents and provide Client proper assistance (at its expense) sufficient to enable it to obtain patent, copyright or other legal
protections for any such inventions or innovations as described in paragraph 7.1(a) and (b), and to make and maintain reasonably
detailed accurate records of any such inventions or innovations;

 

(d)  to deliver to Client,
upon termination or expiration of this Agreement, all materials which were provided to CRO under the terms of this Agreement and
which relate to the business of, or belong to, Client or which were provided by Client for the use of its employees, contractors
or consultants;

 

(e)  not to use, publish,
or otherwise disclose (except if properly authorized as a part of the work for Client) any information which is provided to CRO
under the terms of this Agreement including but not limited to any non-public, proprietary or confidential information;

 

(f)  not to disclose or
utilize in the performance of Services for Client any proprietary or confidential information of others or any inventions of CRO
which are not included within the scope of this Agreement;

 

(g)  not to divulge to any
person, firm, or corporation any information received during the course of this service agreement with regard to the personal,
financial, or other affairs of Client or its subsidiaries, and that all such information shall be kept confidential and shall not,
in any manner, be revealed to anyone.

 

h) not to divulge or make known
to any person, firm, or corporation any of the methods, processes, formulae, discoveries, or inventions, and not, in any manner
whatsoever, divulge, publish or otherwise reveal, either directly or indirectly, any knowledge of inventions or devices which CRO
may come into knowledge of solely as a result of and during the terms of CRO agreement with Client and to retain whatever knowledge
secured in trust as a fiduciary for the sole benefit of Client, its successors and assigns.

 

		8.0	Medical and Regulatory

 

		8.1.	Both parties shall promptly notify the other party of any governmental regulatory inspections of
which it becomes aware and which relate to any project covered in the Addenda. Client shall have the right to be present at any
such inspections and shall have primary responsibility for preparing any responses, which may be required, to the extent such responses
relate to the project covered by the Addenda.

 

		8.2.	Client may designate representatives who shall, upon reasonable notice to CRO, have access to and
shall be permitted to review all documents, information, data and/or materials specifically related to the conduct of the projects
covered by the Addenda.

 

		8.3.	CRO will inform Client in writing immediately of any suspected fraud.

 

 

	 

        Confidential
	 

        Page 4 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

		9.0	Independent Contractor Status

 

		9.1	It is understood and agreed that CRO is an independent contractor and will not have any rights
to any of Client benefits, nor for any purposes be deemed or intended to be an employee of Client. CRO agrees to make any payments
or withholding required by the South African Revenue Service.

 

		9.2	It is further understood that CRO is not an agent of Client and is not authorized to bind Client
with respect to any third party.

 

		10.0	Conflicts of Interest

 

		10.1.	CRO represents that there is no conflict of interest between performance of this Agreement and
the performance of services by CRO for any other party. In the event that CRO believes that there is presently any such conflict,
or any such conflict arises during the term of this Agreement, CRO will immediately notify Client which may, at its sole discretion,
immediately terminate this Agreement without liability to CRO.

 

		11.0	Notices

 

		11.1.	Any notice will be in writing and will be given by registered mail, return receipt requested, or
hand delivered to the other party at the address given on this agreement or to such other address as may be substituted by notice.
If sent by mail, notice will be effective on the date of receipt.

 

		12.0	General Provisions

 

		12.1	CRO will not assign any right or delegate any obligation under this Agreement without the prior
written consent of Client. Any attempted assignment or delegation without such consent will be void.

 

		12.2	The headings in this Agreement are for reference purposes only; they will not affect the meaning
or construction of the terms of this Agreement.

 

		12.3	If any parts or part of this Agreement are held to be invalid, the remaining parts of the Agreement
will continue to be valid and enforceable.

 

		12.4.	The provisions of this Agreement are for the sole benefit of the parties, and not for the benefit
of any other persons or entities.

 

		12.5	Any action of any kind by either party arising out of this Agreement must be commenced within five
(5) years from the date the right, claim, demand, or cause of action shall first arise.

 

		12.6	This Agreement contains the complete and exclusive understanding
of the parties with respect to the subject matter hereof. No waiver, alteration or modification of any of the provisions hereof
will be binding unless in writing and signed by a duly authorized representative of the party to be bound. Neither the course
of conduct between the parties nor trade usage will act to modify or alter the provisions of this Agreement.

 

		12.7	This Agreement shall be governed by the laws of the State of Connecticut, U.S.A. without regard
to conflict of law principles.

 

 

	 

        Confidential
	 

        Page 5 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

BANKING DETAILS

 

[***]

Fur the purposes of invoicing, invoices shall be addressed
to:

 

Purinix Pharmaceuticals LLC

[***]

Att: Chief Executive Officer

 

	CRO	 	Client
	 	 	 
	Signature	/s/ Michael Derby	 	Signature	/s/ Catherine Lund
	 	 	 	 	 
	Name	Michael Derby	 	Name	Catherine Lund
	 	 	 	 	 
	Title	CEO	 	Title	Managing Director
	 	 	 	 	 
	Date	25/05/2008	 	Date	25/05/2008

 

 

	 

        Confidential
	 

        Page 6 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1

 

     

     

    

 

Certain identified information has been
excluded because it is both not material and would

likely cause competitive
harm if publicly disclosed.

 

ADDENDA 1

 

Clinical Protocol Synopsis of Phase 2B Study using [***]to
Treat Children with Autism Spectrum Disorder

 

PAYMENT SCHEDULE (USD)

 

With reference to OnQ proposal v3 13/04/2018

 

[***]

 

Signature of Contract: 20% of Professional Fees

 

	OnQ costs	 	 
	Monitoring	[***]	[***]
	Office overhead	[***]	[***]
	Data Management	[***]	[***]
	 	[***]	[***]

 

	Milestone	Percentage	USD ( amount)
	Signature of contract	 	 
	SAHPRA approval	15%	[***]
	FPI	5%	[***]
	50% recruitment	20%	[***]
	100% recruitment	20%	[***]
	DB lock	10%	[***]
	CSR Draft	10%	[***]
	Acceptance of Final CSR	Final Payment	[***]

 

 

	 

        Confidential
	 

        Page 7 of 7
	 

        Initials:
	CL	 	MD

 

Version Jan16_v1Exhibit 10.1

 

AMENDMENT AND WAIVER

TO EXCLUSIVE SOFTWARE LICENSE & DISTRIBUTON
AGREEMENT

 

This Amendment and
Waiver to Exclusive Software License and Distribution Agreement (the “Amendment”) is dated as of June 30, 2020
and amends that certain Exclusive Software License and Distribution Agreement (the “License Agreement”), with
an effective date as of June 1, 2020, by and among Cranes Software International Ltd., a company organized under the laws of India
(“Cranes” which expression shall include its successors and permitted assigns wherever the context or meaning
shall so require or permit), with a principal office located at #82 Presidency Building 3 & 4th Floor St. Mark's
Road Bengaluru 560001, Systat Software, Inc., a Delaware corporation (“Systat” which expression shall include
its successors and permitted assigns wherever the context or meaning shall so require or permit, with a principal office at 2107
North First Street, Suite 360, San Jose, CA 95131 USA (Systat, Cranes and each of their direct and indirect subsidiaries shall
hereinafter be collectively referred to as the “Systat Parties”), and Inpixon, a Nevada corporation, with a
principal office at 2479 East Bayshore Road, Suite 195, Palo Alto, CA 94303 (“Inpixon” which expression shall
include its successors and assigns wherever the context or meaning shall so require or permit). All capitalized terms that are
used and not defined elsewhere in this Amendment shall have the respective meanings assigned thereto in the License Agreement.

 

RECITALS

 

WHEREAS, the
closing of the transactions contemplated by the License Agreement are subject to the satisfaction of certain conditions set forth
in Article 8 of the License Agreement; and

 

WHEREAS, Section
10.6 of the License Agreement requires any amendment to the License Agreement to be signed by each of the Parties; and

 

WHEREAS, the
Parties desire to proceed with the closing of the transactions described in the License Agreement as of June 30, 2020; and

 

WHEREAS, in
connection with such closing, the Parties agree to waive certain of the closing delivery requirements set forth in Article 8 of
the License Agreement, to be provided within ten (10) business days of the Closing Date (“Extension Date”),
provided, however, that the Cash Consideration may not, at Inpixon’s option, be delivered prior to the later of the Extension
Date or the date on which all such closing deliverables are actually delivered to Inpixon (the “Delivery Date”).

 

NOW, THEREFORE,
Inpixon and the Systat Parties, hereby agree as follows:

 

1. 
Article 8 Waivers. The Parties agree to extend the the delivery requirements set forth in (i) Section 8.2(f), (g)
and (h) and (ii) Section 8.2(c), (d), and (f) until the Extension Date. In addition, the Systat Parties agree that the delivery
and receipt of the Cash Consideration portion of the Closing Consideration required to be delivered in accordance with Section
8.2(i) and 8.3(e) of the License Agreement will be waived until the Delivery Date and the Closing Note shall be delivered on the
Closing Date.

 

2. 
Amendment. Section 3.1 of the License Agreement is hereby amended and restated as follows:

 

“Consideration and
Assignment. In consideration of the rights granted by Systat to Inpixon pursuant to this Agreement, Inpixon shall deliver
the following consideration to Systat (the “Total Consideration”):

 

(a) 
Two Million Two Hundred Thousand Dollars (USD $2,200,000 Million) in cash (the “Cash Consideration”) payable
by wire transfer of immediately available funds to an account to be designated by Systat on or before the Delivery Date.

 

    1

     

    

 

(b) 
An assignment of a portion of that certain promissory note held by Inpixon and payable to Inpixon by Sysorex, Inc. (“Sysorex”),
for up to an aggregate principal amount of Six Million Three Hundred Thousand Dollars (USD $6,300,000) (the “Note”),
including the underlying rights and obligations of Inpixon under the Note, in accordance with the terms and conditions of the assignment
agreement in substantially the form attached hereto as Exhibit B (“License Note Assignment”) and the
intercreditor agreement in substantially the form attached hereto as Exhibit C (the “Intercreditor Agreement”)
as follows:

 

(i) 
$3.0 million on the Closing Date (the “Closing Note”, together with the Cash Consideration the Closing Consideration”);

 

(ii) 
$1.3 million on the three month anniversary of the Closing Date; 

 

(iii) $1.0
million on the six month anniversary of the Closing Date; and

 

(iv) 
$1.0 million on the nine month anniversary of the Closing Date.”

 

3. 
Ratification; No Other Amendment. This Amendment hereby amends the License Agreement effective as of the date hereof
and is deemed to form a part thereof, mutatis mutandis. The License Agreement is hereby ratified and confirmed in all respects,
and all other terms and conditions of the License Agreement, including without limitation the representations, warranties, covenants
and agreements of the respective parties, shall remain in full force and effect without other or further amendment or modification.
On and after the date of this Amendment, any reference to “this Agreement” in the License Agreement and in any other
agreements will mean the License Agreement, as amended by this Amendment. In the event of any conflict between the terms and conditions
of this Amendment, and terms and conditions of the License Agreement, the terms and conditions of this Amendment shall prevail
to the extent of the inconsistency.

 

4. 
Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed an original, but all
of which together shall be deemed to be one and the same agreement. A signed copy of this Amendment delivered by facsimile, email
or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy
of this Amendment.

 

5. 
Governing Law. This Amendment swill be governed by and construed under the laws of the State of California without
regard to conflicts-of-laws principles that would require the application of any other Law. Any proceeding arising out of or relating
to this Amendment shall be brought in the state or federal courts located in San Francisco or Santa Clara County, California, and
each Party irrevocably submits to the exclusive jurisdiction of each such court in any such proceeding, waives any objection it
may now or hereafter have to venue or to convenience of forum, agrees that all claims in respect of the proceeding shall be heard
and determined only in any such court and agrees not to bring any proceeding arising out of or relating to this Amendment in any
other court

 

6. 
Termination. The parties agree that if, for any reason, the License Agreement is terminated in accordance with its
terms prior to closing of the transactions contemplated thereunder, this Amendment will also terminate and be of no further force
or effect.

 

[Signature page follows]

 

    2

     

    

 

IN WITNESS HEREOF,
the Parties represent and warrant that this Amendment is executed by duly authorized representatives of each Party on the date
set forth below.

  

	INPIXON	 	CRANES SOFTWARE INTERNATIONAL LTD.
	 	 	 	 	 
	By:	/s/ Nadir Ali	 	By:	/s/ Asif Khader
	 	 	 	 	 
	Name:	Nadir Ali	 	Name:	Asif Khader
	 	 	 	 	 
	Title:	CEO	 	Title:	Managing Director
	 	 	 	 	 
	Date:	06-30-2020	 	Date:	06-30-2020
	 	 	 	 	 
	 	 	 	SYSTAT SOFTWARE, INC.
	 	 	 	 	 
	 	 	 	By:	/s/ Tanveer A. Khader
	 	 	 	 	 
	 	 	 	Name:	Tanveer A. Khader
	 	 	 	 	 
	 	 	 	Title:	Vice President
	 	 	 	 	 
	 	 	 	Date:	06-30-2020

 

[SIGNATURE PAGE TO AMENDMENT AND WAIVER]

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]